These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6329369)

  • 1. Selection of particles and proteins for use as human cytomegalovirus subunit vaccines.
    Gibson W; Irmiere A
    Birth Defects Orig Artic Ser; 1984; 20(1):305-24. PubMed ID: 6329369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation and characterization of a noninfectious virion-like particle released from cells infected with human strains of cytomegalovirus.
    Irmiere A; Gibson W
    Virology; 1983 Oct; 130(1):118-33. PubMed ID: 6314643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of phosphoproteins and protein kinase activity of virions, noninfectious enveloped particles, and dense bodies of human cytomegalovirus.
    Roby C; Gibson W
    J Virol; 1986 Sep; 59(3):714-27. PubMed ID: 3016333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human cytomegalovirions and dense bodies: glycopeptide analysis and mechanism of cell rounding and polykaryocytosis.
    Sarov I; Abady I
    Isr J Med Sci; 1977 Sep; 13(9):887-95. PubMed ID: 200587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PREPS and L-particles: a new approach to virus-like particle vaccines.
    Pardoe I; Dargan D
    Expert Rev Vaccines; 2002 Dec; 1(4):427-32. PubMed ID: 12901580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers.
    Schneider-Ohrum K; Cayatte C; Liu Y; Wang Z; Irrinki A; Cataniag F; Nguyen N; Lambert S; Liu H; Aslam S; Duke G; McCarthy MP; McCormick L
    J Virol; 2016 Nov; 90(22):10133-10144. PubMed ID: 27581989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low multiplicity cytomegalovirus infection of human aortic smooth muscle cells increases levels of major histocompatibility complex class I antigens and induces a proinflammatory cytokine milieu in the absence of cytopathology.
    Arkonac B; Mauck KA; Chou S; Hosenpud JD
    J Heart Lung Transplant; 1997 Oct; 16(10):1035-45. PubMed ID: 9361246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the cytosolic domains of the hepatitis B virus envelope proteins for their function in viral particle assembly and infectivity.
    Blanchet M; Sureau C
    J Virol; 2006 Dec; 80(24):11935-45. PubMed ID: 17020942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals.
    Grubman MJ
    Biologicals; 2005 Dec; 33(4):227-34. PubMed ID: 16289996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of virion incorporation of Ebolavirus glycoprotein: effects on attachment, cellular entry and neutralization.
    Marzi A; Wegele A; Pöhlmann S
    Virology; 2006 Sep; 352(2):345-56. PubMed ID: 16777170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity.
    Gripon P; Le Seyec J; Rumin S; Guguen-Guillouzo C
    Virology; 1995 Nov; 213(2):292-9. PubMed ID: 7491754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human cytomegalovirus UL130 protein promotes endothelial cell infection through a producer cell modification of the virion.
    Patrone M; Secchi M; Fiorina L; Ierardi M; Milanesi G; Gallina A
    J Virol; 2005 Jul; 79(13):8361-73. PubMed ID: 15956581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle.
    Young KR; Smith JM; Ross TM
    Virology; 2004 Oct; 327(2):262-72. PubMed ID: 15351214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human cytomegalovirus pUS24 is a virion protein that functions very early in the replication cycle.
    Feng X; Schröer J; Yu D; Shenk T
    J Virol; 2006 Sep; 80(17):8371-8. PubMed ID: 16912288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus assemblin (pUL80a): cleavage at internal site not essential for virus growth; proteinase absent from virions.
    Chan CK; Brignole EJ; Gibson W
    J Virol; 2002 Sep; 76(17):8667-74. PubMed ID: 12163586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fish vaccine antigens produced or delivered by recombinant DNA technologies.
    Leong JC; Anderson E; Bootland LM; Chiou PW; Johnson M; Kim C; Mourich D; Trobridge G
    Dev Biol Stand; 1997; 90():267-77. PubMed ID: 9270855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.
    Wang Z; La Rosa C; Lacey SF; Maas R; Mekhoubad S; Britt WJ; Diamond DJ
    J Clin Virol; 2006 Mar; 35(3):324-31. PubMed ID: 16388983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications.
    Smith ML; Lindbo JA; Dillard-Telm S; Brosio PM; Lasnik AB; McCormick AA; Nguyen LV; Palmer KE
    Virology; 2006 May; 348(2):475-88. PubMed ID: 16466765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine.
    Frey SE; Harrison C; Pass RF; Yang E; Boken D; Sekulovich RE; Percell S; Izu AE; Hirabayashi S; Burke RL; Duliège AM
    J Infect Dis; 1999 Nov; 180(5):1700-3. PubMed ID: 10515836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human cytomegalovirus virion proteins.
    Britt WJ; Boppana S
    Hum Immunol; 2004 May; 65(5):395-402. PubMed ID: 15172437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.